A M Cornall1,2,3, M Poljak4,5, S M Garland4,5,6, S Phillips4,5, J H Tan6,7, D A Machalek4,5, M A Quinn6,7, S N Tabrizi4,5,6. 1. Regional HPV Lab Net Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville, 3052, Victoria, Australia. Alyssa.Cornall@mcri.edu.au. 2. Murdoch Childrens Research Institute, Parkville, 3052, Victoria, Australia. Alyssa.Cornall@mcri.edu.au. 3. Department of Obstetrics and Gynecology, University of Melbourne, Parkville, 3052, Victoria, Australia. Alyssa.Cornall@mcri.edu.au. 4. Regional HPV Lab Net Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville, 3052, Victoria, Australia. 5. Murdoch Childrens Research Institute, Parkville, 3052, Victoria, Australia. 6. Department of Obstetrics and Gynecology, University of Melbourne, Parkville, 3052, Victoria, Australia. 7. Oncology and Dysplasia Unit, Royal Women's Hospital, Parkville, 3052, Victoria, Australia.
Abstract
PURPOSE: to evaluate the performance of Anyplex II HPV28 and HPV HR Detection assays against the EuroArray HPV, Cobas 4800 HPV (Cobas), HPV Amplicor (Amp), Linear Array HPV (LA) and Hybrid Capture 2 (HC2) in detection of high-risk HPV (HR-HPV) from liquid-based cervical cytology samples. METHODS: cervical specimens from 404 women undergoing management of high-grade cytological abnormality were evaluated by Anyplex II HPV28 and HPV HR Detection assays for detection of HR-HPV genotypes and prediction of histologically-confirmed cervical intraepithelial neoplasia grade 2 or higher (≥CIN2). The results were compared to EuroArray, HC2, Cobas, Amp, and LA. RESULTS: specimens were evaluated from 404 women with an average age of 30 years, including 336 with a histological diagnosis of ≥ CIN2 and 68 with ≤ CIN1. Concordance of HR-HPV detection between Anyplex II HPV28 and other genotyping assays was 94.79 % (κ = 0.84; EuroArray) and 97.27 % (κ = 0.91; LA); and between Anyplex II HPV HR and other HR-HPV detection assays was 86.35 % (κ = 0.62; HC2), 96.03 % (κ = 0.87; Cobas) and 96.77 % (κ = 0.89; Amp). Using HR-HPV detection for prediction of ≥ CIN2 by Anyplex II HPV28 and HPV HR, sensitivity (90.18, 95 % CI 86.48-93.14; 90.77, 95 % CI 87.16-93.65) and specificity (both 67.16, 95 % CI 54.60-78.15) were not significantly different to the other HPV assays tested, with one exception. Both Anyplex assays had significantly higher sensitivity than HC2 (p < 0.0001), with a specificity of 96 % (p > 0.05) of HC2 in this high-risk population. CONCLUSIONS: both Anyplex II HPV detection assays were concordant with other commercial assays for HR-HPV detection, with comparable sensitivity and specificity for ≥ CIN2 detection.
PURPOSE: to evaluate the performance of Anyplex II HPV28 and HPV HR Detection assays against the EuroArray HPV, Cobas 4800 HPV (Cobas), HPV Amplicor (Amp), Linear Array HPV (LA) and Hybrid Capture 2 (HC2) in detection of high-risk HPV (HR-HPV) from liquid-based cervical cytology samples. METHODS: cervical specimens from 404 women undergoing management of high-grade cytological abnormality were evaluated by Anyplex II HPV28 and HPV HR Detection assays for detection of HR-HPV genotypes and prediction of histologically-confirmed cervical intraepithelial neoplasia grade 2 or higher (≥CIN2). The results were compared to EuroArray, HC2, Cobas, Amp, and LA. RESULTS: specimens were evaluated from 404 women with an average age of 30 years, including 336 with a histological diagnosis of ≥ CIN2 and 68 with ≤ CIN1. Concordance of HR-HPV detection between Anyplex II HPV28 and other genotyping assays was 94.79 % (κ = 0.84; EuroArray) and 97.27 % (κ = 0.91; LA); and between Anyplex II HPV HR and other HR-HPV detection assays was 86.35 % (κ = 0.62; HC2), 96.03 % (κ = 0.87; Cobas) and 96.77 % (κ = 0.89; Amp). Using HR-HPV detection for prediction of ≥ CIN2 by Anyplex II HPV28 and HPV HR, sensitivity (90.18, 95 % CI 86.48-93.14; 90.77, 95 % CI 87.16-93.65) and specificity (both 67.16, 95 % CI 54.60-78.15) were not significantly different to the other HPV assays tested, with one exception. Both Anyplex assays had significantly higher sensitivity than HC2 (p < 0.0001), with a specificity of 96 % (p > 0.05) of HC2 in this high-risk population. CONCLUSIONS: both Anyplex II HPV detection assays were concordant with other commercial assays for HR-HPV detection, with comparable sensitivity and specificity for ≥ CIN2 detection.
Authors: S Phillips; A M Cornall; D A Machalek; S M Garland; D Bateson; M Garefalakis; S N Tabrizi Journal: Eur J Clin Microbiol Infect Dis Date: 2016-05-13 Impact factor: 3.267
Authors: Samuel Phillips; Suzanne M Garland; Jeffery H Tan; Michael A Quinn; Sepehr N Tabrizi Journal: J Clin Virol Date: 2014-11-18 Impact factor: 3.168
Authors: Thomas C Wright; Mark H Stoler; Catherine M Behrens; Abha Sharma; Guili Zhang; Teresa L Wright Journal: Gynecol Oncol Date: 2015-01-08 Impact factor: 5.482
Authors: Matthew P Stevens; Suzanne M Garland; Elice Rudland; Jeffrey Tan; Michael A Quinn; Sepehr N Tabrizi Journal: J Clin Microbiol Date: 2007-05-09 Impact factor: 5.948
Authors: Chris J L M Meijer; Johannes Berkhof; Philip E Castle; Albertus T Hesselink; Eduardo L Franco; Guglielmo Ronco; Marc Arbyn; F Xavier Bosch; Jack Cuzick; Joakim Dillner; Daniëlle A M Heideman; Peter J F Snijders Journal: Int J Cancer Date: 2009-02-01 Impact factor: 7.396
Authors: A M Cornall; M Poljak; S M Garland; S Phillips; D A Machalek; J H Tan; M A Quinn; S N Tabrizi Journal: Eur J Clin Microbiol Infect Dis Date: 2016-04-05 Impact factor: 3.267
Authors: Luana L S Rodrigues; Mariza G Morgado; Vikrant V Sahasrabuddhe; Vanessa S De Paula; Nathália S Oliveira; Elena Chavez-Juan; Diane M Da Silva; W Martin Kast; Alcina F Nicol; José H Pilotto Journal: Gynecol Oncol Date: 2018-08-04 Impact factor: 5.482
Authors: François Coutlée; Alexandra de Pokomandy; Ann N Burchell; Mariam El-Zein; Marie-Hélène Mayrand; Sophie Rodrigues-Coutlée; Deborah Money; Émilie Comète; Elisabeth McClymont; Danielle Rouleau; Eduardo L Franco Journal: J Med Virol Date: 2022-01-28 Impact factor: 20.693
Authors: Alyssa M Cornall; Marin Poljak; Suzanne M Garland; Samuel Phillips; Dorothy A Machalek; Jeffrey H Tan; Michael A Quinn; Sepehr N Tabrizi Journal: Papillomavirus Res Date: 2017-10-18
Authors: Kandali Samwel; Crispin Kahesa; Julius Mwaiselage; Daniela Gonzalez; John T West; Charles Wood; Joel Palefsky; Peter C Angeletti Journal: J Med Virol Date: 2018-10-22 Impact factor: 2.327